HomeCompareFCNVX vs JNJ

FCNVX vs JNJ: Dividend Comparison 2026

FCNVX yields 4.30% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCNVX wins by $6.5K in total portfolio value
10 years
FCNVX
FCNVX
● Live price
4.30%
Share price
$10.06
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.09
Full FCNVX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — FCNVX vs JNJ

📍 FCNVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFCNVXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FCNVX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FCNVX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FCNVX
Annual income on $10K today (after 15% tax)
$365.78/yr
After 10yr DRIP, annual income (after tax)
$482.03/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $221.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FCNVX + JNJ for your $10,000?

FCNVX: 50%JNJ: 50%
100% JNJ50/50100% FCNVX
Portfolio after 10yr
$23.3K
Annual income
$697.43/yr
Blended yield
3.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FCNVX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FCNVX buys
0
JNJ buys
0
No recent congressional trades found for FCNVX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFCNVXJNJ
Forward yield4.30%3.36%
Annual dividend / share$0.43$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$26.5K$20.0K
Annual income after 10y$567.09$827.78
Total dividends collected$5.0K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FCNVX vs JNJ ($10,000, DRIP)

YearFCNVX PortfolioFCNVX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,130$430.33$10,676$355.77+$454.00FCNVX
2$12,357$447.63$11,407$389.39+$950.00FCNVX
3$13,687$464.46$12,198$426.53+$1.5KFCNVX
4$15,125$480.78$13,056$467.62+$2.1KFCNVX
5$16,681$496.56$13,987$513.12+$2.7KFCNVX
6$18,360$511.79$14,998$563.56+$3.4KFCNVX
7$20,172$526.47$16,098$619.52+$4.1KFCNVX
8$22,124$540.58$17,295$681.69+$4.8KFCNVX
9$24,227$554.12$18,599$750.82+$5.6KFCNVX
10$26,490$567.09$20,022$827.78+$6.5KFCNVX

FCNVX vs JNJ: Complete Analysis 2026

FCNVXStock

The fund normally invests at least 80% of assets in U.S. dollar-denominated money market and high quality investment-grade debt securities of all types, and repurchase agreements for those securities. It invests more than 25% of total assets in the financial services industries. The fund normally maintains a dollar-weighted average maturity of 0.75 years or less. It invests in fixed rate securities with a maximum maturity of two years or less and floating rate securities with a maximum maturity of three years or less.

Full FCNVX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this FCNVX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FCNVX vs SCHDFCNVX vs JEPIFCNVX vs OFCNVX vs KOFCNVX vs MAINFCNVX vs ABBVFCNVX vs MRKFCNVX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.